Systemic inflammation has been associated with chemoresistance and prognosis in solid tumors. Systemic immune-inflammation index (SII) is a novel marker derived from complete blood count. We investigated whether differences between SIIs measured before and after neoadjuvant chemotherapy (NACT) are associated with tumor regression grade (TRG) and survival in gastric and gastroesophageal junction (GEJ) cancer patients.

中文翻译：

---

全身免疫炎症指数的动态变化预测接受新辅助化疗的胃癌或胃食管结合部癌患者的病理肿瘤反应和总生存期

全身性炎症与实体瘤的化疗耐药性和预后有关。全身免疫炎症指数 (SII) 是一种源自全血细胞计数的新型标志物。我们研究了新辅助化疗 (NACT) 前后测量的 SII 之间的差异是否与胃癌和胃食管结合部 (GEJ) 癌患者的肿瘤消退等级 (TRG) 和生存相关。